EFFECTIVENESS OF COMPOUND DANSHEN DRIPPING PILLS IN SUPPORTING PHYSICAL ACTIVITY AND CARDIOVASCULAR HEALTH IN PATIENTS WITH CORONARY HEART DISEASE AND ANGINA PECTORIS

Abstract

Objective: This study evaluates the clinical efficacy of Compound Danshen Dripping Pills in conjunction with Yangxinshi tablets in patients with coronary heart disease and angina pectoris. The research specifically assessed symptom remission, quality of life enhancements, and the influence on postoperative adverse cardiovascular events, alongside changes in blood lipids and ejection fraction (EF%). Methods: In a randomized controlled trial, 40 patients diagnosed with coronary heart disease were equally divided into a treatment group and a control group. The treatment group received 0.5g of Compound Danshen Dripping Pills three times daily post-meal, and a placebo equivalent to Yangxinshi tablets. Conversely, the control group was administered Yangxinshi tablets (1.8g, three times daily after meals) and a placebo mimicking the dosage of the Compound Danshen Dripping Pills. Results: Both groups consisted of 20 patients each. Initial assessments showed no significant differences in general clinical data, coronary artery disease characteristics, or procedural metrics between the groups. Key findings included: Improvement in angina pectoris symptoms as measured by the Seattle Angina Pectoris Scale, showing better scores in the treatment group compared to the control. Ejection fraction (EF%) showed improvements post-treatment but did not differ significantly between the groups. Reduction in high-sensitivity C-reactive protein (Hs-CRP) levels was observed three months post-treatment, indicating a reduction in inflammation. Lipid profile analysis revealed lower levels of cholesterol (CHOL), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C), and an increase in high-density lipoprotein cholesterol (HDL-C) post-treatment, although these changes were not significantly different between groups. Safety assessments confirmed that liver and kidney functions remained stable, with no severe adverse reactions reported, attesting to the safety of Compound Danshen Dripping Pills. Conclusion: Compound Danshen Dripping Pills, when used alongside Yangxinshi tablets, demonstrate a significant therapeutic effect on patients with coronary heart disease and angina pectoris. The treatment improved symptoms related to angina pectoris, enhanced myocardial metabolism, and potentially improved hemorheology and coronary circulation. These benefits suggest that Compound Danshen Dripping Pills could be an effective component of integrated treatment strategies for enhancing cardiac health and physical activity levels in this patient population. Further studies are recommended to validate these findings and explore long-term benefits and mechanisms of action.